![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SCRN2 |
Gene summary for SCRN2 |
![]() |
Gene information | Species | Human | Gene symbol | SCRN2 | Gene ID | 90507 |
Gene name | secernin 2 | |
Gene Alias | Ses2 | |
Cytomap | 17q21.32 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q96FV2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
90507 | SCRN2 | male-WTA | Human | Thyroid | PTC | 5.22e-19 | 1.35e-01 | 0.1037 |
90507 | SCRN2 | PTC01 | Human | Thyroid | PTC | 7.80e-18 | 3.77e-01 | 0.1899 |
90507 | SCRN2 | PTC04 | Human | Thyroid | PTC | 2.61e-16 | 1.87e-01 | 0.1927 |
90507 | SCRN2 | PTC05 | Human | Thyroid | PTC | 3.07e-12 | 6.12e-01 | 0.2065 |
90507 | SCRN2 | PTC06 | Human | Thyroid | PTC | 4.29e-27 | 5.80e-01 | 0.2057 |
90507 | SCRN2 | PTC07 | Human | Thyroid | PTC | 9.53e-30 | 5.05e-01 | 0.2044 |
90507 | SCRN2 | ATC12 | Human | Thyroid | ATC | 1.14e-25 | 2.68e-01 | 0.34 |
90507 | SCRN2 | ATC13 | Human | Thyroid | ATC | 4.75e-03 | -6.34e-02 | 0.34 |
90507 | SCRN2 | ATC2 | Human | Thyroid | ATC | 5.73e-03 | 2.07e-01 | 0.34 |
90507 | SCRN2 | ATC4 | Human | Thyroid | ATC | 6.44e-20 | 3.72e-01 | 0.34 |
90507 | SCRN2 | ATC5 | Human | Thyroid | ATC | 1.39e-02 | -6.36e-02 | 0.34 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SCRN2 | SNV | Missense_Mutation | c.828N>G | p.Ile276Met | p.I276M | Q96FV2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SCRN2 | SNV | Missense_Mutation | rs766421033 | c.433N>A | p.Gly145Arg | p.G145R | Q96FV2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
SCRN2 | SNV | Missense_Mutation | novel | c.292G>A | p.Glu98Lys | p.E98K | Q96FV2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SCRN2 | deletion | Frame_Shift_Del | c.328delN | p.Glu110LysfsTer25 | p.E110Kfs*25 | Q96FV2 | protein_coding | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
SCRN2 | SNV | Missense_Mutation | rs144133774 | c.1040N>A | p.Arg347Gln | p.R347Q | Q96FV2 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
SCRN2 | SNV | Missense_Mutation | c.8N>T | p.Ser3Leu | p.S3L | Q96FV2 | protein_coding | tolerated_low_confidence(0.16) | benign(0) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SCRN2 | SNV | Missense_Mutation | rs374214556 | c.1079N>A | p.Arg360His | p.R360H | Q96FV2 | protein_coding | deleterious(0.02) | benign(0.373) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
SCRN2 | SNV | Missense_Mutation | rs779903206 | c.1243N>A | p.Ala415Thr | p.A415T | Q96FV2 | protein_coding | tolerated(0.1) | benign(0) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
SCRN2 | SNV | Missense_Mutation | rs751802544 | c.566N>A | p.Arg189His | p.R189H | Q96FV2 | protein_coding | deleterious(0.02) | benign(0.013) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SCRN2 | deletion | Frame_Shift_Del | rs750983392 | c.437delG | p.Gly146AlafsTer50 | p.G146Afs*50 | Q96FV2 | protein_coding | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |